Cargando…

Dosimetric verification of IMPT using a commercial heterogeneous phantom

The purpose of this study was to propose a verification method and results of intensity‐modulated proton therapy (IMPT), using a commercially available heterogeneous phantom. We used a simple simulated head and neck and prostate phantom. An ionization chamber and radiochromic film were used for meas...

Descripción completa

Detalles Bibliográficos
Autores principales: Yasui, Keisuke, Toshito, Toshiyuki, Omachi, Chihiro, Hayashi, Kensuke, Kinou, Hideto, Katsurada, Masaki, Hayashi, Naoki, Ogino, Hiroyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6371016/
https://www.ncbi.nlm.nih.gov/pubmed/30673145
http://dx.doi.org/10.1002/acm2.12535
_version_ 1783394476844122112
author Yasui, Keisuke
Toshito, Toshiyuki
Omachi, Chihiro
Hayashi, Kensuke
Kinou, Hideto
Katsurada, Masaki
Hayashi, Naoki
Ogino, Hiroyuki
author_facet Yasui, Keisuke
Toshito, Toshiyuki
Omachi, Chihiro
Hayashi, Kensuke
Kinou, Hideto
Katsurada, Masaki
Hayashi, Naoki
Ogino, Hiroyuki
author_sort Yasui, Keisuke
collection PubMed
description The purpose of this study was to propose a verification method and results of intensity‐modulated proton therapy (IMPT), using a commercially available heterogeneous phantom. We used a simple simulated head and neck and prostate phantom. An ionization chamber and radiochromic film were used for measurements of absolute dose and relative dose distribution. The measured doses were compared with calculated doses using a treatment planning system. We defined the uncertainty of the measurement point of the ionization chamber due to the effective point of the chamber and mechanical setup error as 2 mm and estimated the dose variation base on a 2 mm error. We prepared a HU‐relative stopping power conversion table and fluence correction factor that were specific to the heterogeneous phantom. The fluence correction factor was determined as a function of depth and was obtained from the ratio of the doses in water and in the phantom at the same effective depths. In the simulated prostate plan, composite doses of measurements and calculations agreed within ±1.3% and the maximum local dose differences of each field were 10.0%. Composite doses in the simulated head and neck plan agreed within 4.0% and the maximum local dose difference for each field was 12.0%. The dose difference for each field came within 2% when taking the measurement uncertainty into consideration. In the composite plan, the maximum dose uncertainty was estimated as 4.0% in the simulated prostate plan and 5.8% in the simulated head and neck plan. Film measurements showed good agreement, with more than 92.5% of points passing a gamma value (3%/3 mm). From these results, the heterogeneous phantom should be useful for verification of IMPT by using a phantom‐specific HU‐relative stopping power conversion, fluence correction factor, and dose error estimation due to the effective point of the chamber.
format Online
Article
Text
id pubmed-6371016
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-63710162019-02-21 Dosimetric verification of IMPT using a commercial heterogeneous phantom Yasui, Keisuke Toshito, Toshiyuki Omachi, Chihiro Hayashi, Kensuke Kinou, Hideto Katsurada, Masaki Hayashi, Naoki Ogino, Hiroyuki J Appl Clin Med Phys Radiation Oncology Physics The purpose of this study was to propose a verification method and results of intensity‐modulated proton therapy (IMPT), using a commercially available heterogeneous phantom. We used a simple simulated head and neck and prostate phantom. An ionization chamber and radiochromic film were used for measurements of absolute dose and relative dose distribution. The measured doses were compared with calculated doses using a treatment planning system. We defined the uncertainty of the measurement point of the ionization chamber due to the effective point of the chamber and mechanical setup error as 2 mm and estimated the dose variation base on a 2 mm error. We prepared a HU‐relative stopping power conversion table and fluence correction factor that were specific to the heterogeneous phantom. The fluence correction factor was determined as a function of depth and was obtained from the ratio of the doses in water and in the phantom at the same effective depths. In the simulated prostate plan, composite doses of measurements and calculations agreed within ±1.3% and the maximum local dose differences of each field were 10.0%. Composite doses in the simulated head and neck plan agreed within 4.0% and the maximum local dose difference for each field was 12.0%. The dose difference for each field came within 2% when taking the measurement uncertainty into consideration. In the composite plan, the maximum dose uncertainty was estimated as 4.0% in the simulated prostate plan and 5.8% in the simulated head and neck plan. Film measurements showed good agreement, with more than 92.5% of points passing a gamma value (3%/3 mm). From these results, the heterogeneous phantom should be useful for verification of IMPT by using a phantom‐specific HU‐relative stopping power conversion, fluence correction factor, and dose error estimation due to the effective point of the chamber. John Wiley and Sons Inc. 2019-01-23 /pmc/articles/PMC6371016/ /pubmed/30673145 http://dx.doi.org/10.1002/acm2.12535 Text en © 2019 The Authors. Journal of Applied Clinical Medical Physics published by Wiley Periodicals, Inc. on behalf of American Association of Physicists in Medicine This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Radiation Oncology Physics
Yasui, Keisuke
Toshito, Toshiyuki
Omachi, Chihiro
Hayashi, Kensuke
Kinou, Hideto
Katsurada, Masaki
Hayashi, Naoki
Ogino, Hiroyuki
Dosimetric verification of IMPT using a commercial heterogeneous phantom
title Dosimetric verification of IMPT using a commercial heterogeneous phantom
title_full Dosimetric verification of IMPT using a commercial heterogeneous phantom
title_fullStr Dosimetric verification of IMPT using a commercial heterogeneous phantom
title_full_unstemmed Dosimetric verification of IMPT using a commercial heterogeneous phantom
title_short Dosimetric verification of IMPT using a commercial heterogeneous phantom
title_sort dosimetric verification of impt using a commercial heterogeneous phantom
topic Radiation Oncology Physics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6371016/
https://www.ncbi.nlm.nih.gov/pubmed/30673145
http://dx.doi.org/10.1002/acm2.12535
work_keys_str_mv AT yasuikeisuke dosimetricverificationofimptusingacommercialheterogeneousphantom
AT toshitotoshiyuki dosimetricverificationofimptusingacommercialheterogeneousphantom
AT omachichihiro dosimetricverificationofimptusingacommercialheterogeneousphantom
AT hayashikensuke dosimetricverificationofimptusingacommercialheterogeneousphantom
AT kinouhideto dosimetricverificationofimptusingacommercialheterogeneousphantom
AT katsuradamasaki dosimetricverificationofimptusingacommercialheterogeneousphantom
AT hayashinaoki dosimetricverificationofimptusingacommercialheterogeneousphantom
AT oginohiroyuki dosimetricverificationofimptusingacommercialheterogeneousphantom